EUVIMEDEUVIMED entdecken
Crossref

Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium

Diego Castanares-Zapatero iD, Leen Verleye, Carl Devos, Nancy Thiry, Geert Silversmit, Nancy Van Damme, Cindy De Gendt, Frank Hulstaert, Mattias Neyt

International Journal of Dermatology · 2024

DOI: 10.1111/ijd.17046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2024. Verfasst von Diego Castanares-Zapatero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Ipilimumab, Nivolumab. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Belgian Health Care Knowledge Centre (KCE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although metastatic cutaneous melanoma is associated with an unfavorable prognosis, innovative therapies including immunomodulating agents and targeted therapies have shown survival benefits in clinical trials. We assessed the impact of the introduction of innovative drugs into clinical practice on the survival of patients with metastatic cutaneous melanoma during the period 2004–2017, in Belgium. The evolution of associated expenses was also analyzed.

Methods

This is a retrospective population‐based study using data from the national Belgian Cancer Registry, compulsory health insurance, and administrative survival data. The immunomodulating drugs were ipilimumab, nivolumab and pembrolizumab, while targeted therapies included vemurafenib, dabrafenib and trametinib.

Results

We did not identify a trend for improvement over time. Median survival (years) was 1.5 (95% CI: 1.1–1.8) in 2004–2008, 1.1 (95% CI: 0.8–1.5) in 2009–2013, and 1.6 (95% CI: 1.3–2.4) in 2014–2017, respectively. In contrast, survival improved in those with unknown primary tumor localization. In this group, median survival time was 2.0 (95% CI: 1.4–2.9) in the most recent period, while it was 1.1 (95% CI: 0.7–1.3) in 2009–2013, and 0.9 (95% CI: 0.6–1.2) in 2004–2008. The uptake of innovative drugs remained modest, with no drug being used by more than 30% of patients. Yearly expenditure was almost non‐existent, and gradually increased, reaching several million euros in 2014–2017.

Conclusion

Patients with metastatic cutaneous melanoma who were diagnosed between 2004 and 2017 showed no apparent improvement in survival. In contrast, increased survival was observed in the subgroup of patients with unknown primary tumor localization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsIpilimumabNivolumabAntibodies, Monoclonal, HumanizedOximesHumansBelgiumRetrospective StudiesMaleFemaleMiddle AgedAgedPrognosisPyrimidinonesPyridonesImidazolesVemurafenibAdultRegistriesSurvival RateCutaneous Malignant MelanomaImmune Checkpoint InhibitorsImmunotherapyAged, 80 and over

Substanzen

IpilimumabNivolumabdabrafenibAntibodies, Monoclonal, HumanizedOximespembrolizumabtrametinibPyrimidinonesPyridonesImidazoles

Autor:innen und Institutionen

  • Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium.
  • Belgian Cancer Registry (BCR), Brussels, Belgium.

ORCID-Profile: Diego Castanares-Zapatero

Förderung

  • Belgian Health Care Knowledge Centre (KCE)

Zitieren

APA

Castanares-Zapatero, D., Verleye, L., Devos, C., Thiry, N., Silversmit, G., Van Damme, N., De Gendt, C., Hulstaert, F., & Neyt, M. (2024). Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium. International Journal of Dermatology. https://doi.org/10.1111/ijd.17046

Vancouver

Castanares-Zapatero D, Verleye L, Devos C, Thiry N, Silversmit G, Van Damme N, et al. Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium. International Journal of Dermatology. 2024. doi:10.1111/ijd.17046

BibTeX
@article{CastanaresZapatero2024,
  author = {Castanares-Zapatero, Diego and Verleye, Leen and Devos, Carl and Thiry, Nancy and Silversmit, Geert and Van Damme, Nancy and De Gendt, Cindy and Hulstaert, Frank and Neyt, Mattias},
  title = {Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population‐based study in Belgium},
  journal = {International Journal of Dermatology},
  year = {2024},
  doi = {10.1111/ijd.17046}
}
Kostenlos starten →